Old Web
English
Sign In
Acemap
>
authorDetail
>
Heidi H. Gillenwater
Heidi H. Gillenwater
Bristol-Myers Squibb
Ibrutinib
Medicine
Internal medicine
Cohort
Oncology
4
Papers
33
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
TRANSCEND CLL 004: PHASE 1 COHORT OF LISOCABTAGENE MARALEUCEL (LISO-CEL) COMBINED WITH IBRUTINIB (IBR) FOR PATIENTS (PTS) WITH R/R CLL/SLL
2021
Hematological Oncology
William G. Wierda
Kathleen A. Dorritie
Javier Munoz
Deborah M. Stephens
Scott R. Solomon
Heidi H. Gillenwater
Lucy Gong
Lin Yang
Ken Ogasawara
Jerill Thorpe
Tanya Siddiqi
Show All
Source
Cite
Save
Citations (0)
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
2021
Blood
Tanya Siddiqi
Jacob D. Soumerai
Kathleen A. Dorritie
Deborah M. Stephens
Peter A. Riedell
Jon E. Arnason
Thomas J. Kipps
Heidi H. Gillenwater
Lucy Gong
Lin Yang
Ken Ogasawara
Jerill Thorpe
William G. Wierda
Show All
Source
Cite
Save
Citations (0)
Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients
2020
Blood
Tanya Siddiqi
Jacob D. Soumerai
Kathleen A. Dorritie
Deborah M. Stephens
Peter A. Riedell
Jon E. Arnason
Thomas J. Kipps
Heidi H. Gillenwater
Lucy Gong
Lin Yang
Ken Ogasawara
William G. Wierda
Show All
Source
Cite
Save
Citations (16)
Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
2020
Blood
William G. Wierda
Kathleen A. Dorritie
Javier Munoz
Deborah M. Stephens
Scott R. Solomon
Heidi H. Gillenwater
Lucy Gong
Lin Yang
Ken Ogasawara
Jerill Thorpe
Tanya Siddiqi
Show All
Source
Cite
Save
Citations (17)
1